

**AMENDMENTS TO CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Cancelled)

Claim 2 (Currently amended): A compound according to Claim 1 selected from:

(S)- 1 -[3,4- Dihydroxy-6-hydroxymethyl-5-(3,4,5-trihydroxymethyl tetrahydro-pyran-2- yloxy)-tetrahydro-pyran-2-yl] -4-isobutyl-pyrrolidin 2-one;


(S)-4- Isobutyl- 1 -(2,3,4,5-tetrahydroxy-tetrahydro-pyran 2-ylmethyl)-pyrrolidin-2-one;






(S)- 1- 2,3 -Dihydroxy-5-hydroxymethyl-4-(3,4?5- trihydroxy-6 hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-furan-2- ylmethyl] 4-isobutyl-pyrrolidin-2-one;


(S)-4-Isobutyl- 1 -[2,3,5- trihydroxy-4-(3,4,5-trihydroxy 6-hydroxymethyl-tetrahydro-pyran-2- yloxy)-tetrahydro-pyran-2-ylmethyl] pyrrolidin-2-one; and

(S)-4-Isobutyl- 1 -(2,3,4-trihydroxy-5-hydroxymethyl-tetrahydro furan-2- ylmethyl)- pyrrolidin-2-one.

Claim 3 (Original): A compound according to Claim 2 selected from:







Claim 4 (Currently amended): A pharmaceutical formulation composition comprising at least one compound of Claim 1-2 and a pharmaceutically acceptable carrier, excipient, or diluent thereof.

Claim 5 (Currently amended): A method for treating a subject having a central nervous system disorder or disease by, which method comprises administering to the subject a pharmaceutically effective amount of a compound of Claim 1 selected from:

(S)-1-[3,4-Dihydroxy-6-hydroxymethyl-5-(3,4,5-trihydroxymethyl tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-yl]-4-isobutyl-pyrrolidin 2- one;

(S)-4-Isobutyl- 1 -(2,3,4,5-tetrahydroxy-tetrahydro-pyran 2-ylmethyl) -pyrrolidin-2-one;

(S)-1-[2,3-Dihydroxy-5-hydroxymethyl-4-(3,4,5- trihydroxy-6 hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-furan- 2-ylmethyl] 4-isobutyl-pyrrolidin-2-one;

(S)-4-Isobutyl- 1-[2,3,5- trihydroxy-4-(3,4,5-trihydroxy 6 -hydroxymethyl -te trahydro -p yr an - 2 -yl oxy) -tetrahydro -pyran - 2 - yl methyl] pyrrolidin-2-one;

(S)-4-Isobutyl-1-(2,3,4-trihydroxy-5-hydroxymethyl-tetrabydro furan-2- ylmethyl) -pyrrolidin-2-one; and

a pharmaceutically acceptable salt of any of said compounds.

Claim 6 (Original): A method according to Claim 5 wherein the central nervous system disorder or disease is depression, seizure, anxiety, pain, sleep disorder, consumptive disorder, psychosis, dyskinesia, Huntington's disease, or Parkinson's disease.

Claim 7 (Cancelled)

Appl. No. 10/058,903

Request for Continued Examination

Reply to Office Action of June 03, 2004

Claim 8 (New): A compound according to claim 2 where the compound is in isolated form.